A similar result was obtained in urothelial, melanoma, and non-small cell lung carcinoma in which IFN-γ signaling-related genes, including IFNG, CD274, LAG3, and CXCL9, could well predict about who could benefit from the immunotherapy via anti-PD-L1/PD-1 antibody (62, 63). This evidence concerns the gene LAG3 and melanoma.